Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.

A professor at the Indiana Univesity Luddy School of Informatics, Computing and Engineering has co-authored a paper ...

The global biosimulation market is set for explosive growth, with a new forecast predicting its valuation will increase from ...

Co-authors: Roger Hancock, CEO of Recall InfoLink, and Gillian Kelleher, president and CEO of Kelleher Consultants LLC. -- OPINION -- On July 9, the FDA ...

This review explores how generative AI, through models like VAEs, GANs, transformers, and diffusion networks is ...

Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl–TH023 may fulfill the promise of ...

Digital twin system offers a way to test hypotheses and therapeutics before live cell experimentsA researcher team drawn from ...

Shares of D-Wave Quantum Inc. (NYSE:QBTS) increased by 3.7% following the company’s announcement of a new suite of tools ...

Convexia is an “AI-maximalist pharma company” using autonomous agents to discover, evaluate, and develop overlooked drug ...

Leipzig University just got the world’s largest brain-inspired supercomputer. Could this be the future of drug discovery?

What if concrete could capture carbon and last 2,000 years? AI just made that idea possible, with atomic-scale simulations ...